But that is not the whole picture
BPC-157: Multi-mechanism regenerative effects Tendon and ligament healing: Most robust research exists for BPC-157 tendon repair
Published literature: Documented effects on sleep architecture and cortisol modulation in published studies Therapeutic Peptides Comparison Table Peptide Category FDA Status Primary Research Application BPC-157 Tissue Repair Category 1 (2026) Tendon, ligament, GI repair TB-500 Tissue Repair Category 1 (2026) Soft tissue, cell migration Retatrutide Metabolic Phase 3 trials Obesity, metabolic syndrome Tirzepatide Metabolic FDA-approved Type 2 diabetes, obesity Tesamorelin Metabolic / GH FDA-approved Lipodystrophy, visceral fat GHK-Cu Skin / Repair Not approved Wound healing, collagen CJC-1295 GH Secretagogue Category 1 (2026) Growth hormone release Ipamorelin GH Secretagogue Category 1 (2026) Selective GH release Selank Cognitive Category 1 (2026) Anxiety, GABA modulation Semax Cognitive Category 1 (2026) Memory, BDNF pathways KPV Anti-inflammatory Not approved Gut inflammation, skin PT-141 Neurological FDA-approved Sexual health (HSDD) SS-31 Mitochondrial FDA-approved Barth syndrome, mito dysfunction MOTS-c Mitochondrial Not approved Insulin sensitivity, exercise Humanin Cytoprotective Not approved Neuroprotection, aging DSIP Neurological Not approved Sleep regulation 2026 FDA Peptide Reclassification On February 27, 2026, HHS Secretary Robert F
This might be practical evidence that BPC 157 accordingly manages tendon healing and muscle healing [43,44,45,46,47,48,93,94,95,96,97,98], so that myotendinous junction healing may be achieved [43]
But, like BPC-157, they lack robust human clinical data to confirm their safety or efficacy
